



# Pharmaids Pharmaceuticals Limited

Date: 05.02.2021

To

The Manager  
Department of Corporate Service  
BSE Limited  
PJ Towers, Dalal Street,  
Fort Mumbai-400001.

**BSE Script Code: 524572**

**Subject: Outcome of Board Meeting – February 05, 2021**

**Ref.: Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015 (“Listing Regulations”)**

Dear Sir / Madam,

We inform you that the Board of Directors of the Company, at their meeting held today i.e. Friday, February 05, 2021 has approved the unaudited financial results for the quarter and nine months ended 31 December 2020.

Pursuant to above referred regulations, we enclose the following documents:

- a) Statement of Financial Results for the Quarter and Nine Months ended 31<sup>st</sup> December, 2020.
- b) Limited Review Reports issued by M/s. PPKG & Co, the Statutory Auditors of the Company.


The meeting of the Board of Directors of the Company Commenced at 2.30 PM and concluded at 5.15 PM.

The financial results are also available on the website of the Company at [www.pharmaids.com](http://www.pharmaids.com) and also on the website of BSE Ltd. Viz. [www.bseindia.com](http://www.bseindia.com).

You are requested to take the above information on record.

Thanking You,

Yours faithfully  
For **Pharmaids Pharmaceuticals Limited**

  
S. Padmaja Kalyani  
Director (DIN: 03096445)







# Pharmaids Pharmaceuticals Limited

## Pharmaids Pharmaceuticals Limited

Statement of Unaudited Profit and Loss account for the Third Quarter and Nine Months Period ended 31st December, 2020

Rs. (In Lakhs)

Particulars	Quarter Ended			Nine Months Period Ended		Year ended
	Unaudited (Reviewed)			Unaudited (Reviewed)		Audited
	December 31, 2020	September 30, 2020	December 31, 2019	December 31, 2020	December 31, 2019	March 31, 2020
1 Revenue	341.00	325.58	-	666.58	-	0.00
2 Other Income	-	-	-	2.63	-	0.00
3 <b>Total Income</b>	341.00	325.58	-	669.22	-	-
4 <b>Expenses</b>						
a) Cost of Material Consumed	-	-	-	-	-	0.00
b) Purchase of Stock in Trade	391.69	382.61	-	774.30	-	0.00
c) Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	(57.35)	(70.29)	-	(127.64)	-	0.00
d) Employee Benefit Expenses	1.18	0.60	0.31	2.07	1.82	2.28
e) Finance Cost	-	-	-	-	0.08	0.08
f) Depreciation and Amortisation Expenses	1.13	1.11	0.93	3.36	2.79	3.88
g) Other Expenses	2.44	6.70	18.06	10.02	29.22	31.27
<b>Total Expenses</b>	339.09	320.72	19.30	662.10	33.91	37.52
5 Profit/(loss) before Exceptional Items and Tax	1.91	4.86	(19.30)	7.11	(33.91)	(37.52)
6 Exceptional Items	-	-	-	-	-	-
7 Profit/(loss) before tax	1.91	4.86	(19.30)	7.11	(33.91)	(37.52)
8 Tax expense:						
(1) Current tax	0.95	1.13	-	2.08	-	0.00
(2) Deferred tax	-	-	-	-	-	(40.87)
9 Profit (Loss) for the period from continuing operations	0.97	3.73	(19.30)	5.03	(33.91)	3.35
10 Profit/(loss) from discontinued operations	-	-	-	-	-	-
11 Tax expense of discontinued operations	-	-	-	-	-	-
12 Profit/(loss) from Discontinued operations (after tax)	-	-	-	-	-	-
13 Profit/(loss) for the period	0.97	3.73	(19.30)	5.03	(33.91)	3.35
14 Other Comprehensive Income						
A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
15 Total Comprehensive Income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period)	-	-	-	-	-	-
16 Earnings per equity share (for continuing operation):	0.97	3.73	(19.30)	5.03	(33.91)	3.35
(1) Basic	0.01	0.04	(0.19)	0.05	(0.33)	0.03
(2) Diluted	0.01	0.04	(0.19)	0.05	(0.33)	0.03

**NOTES:** 1. The above results were approved at the meeting of the Board of Directors held on February 05, 2021. 2. The Company operates in a single segment. 3. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation. 4. As per NCLT order dated 27-09-2019, Pharmaids Pharmaceuticals Limited undergone amalgamation with Emergent Bio Naturals Limited w.e.f 01-04-2018 as explained in Para 5 of the Auditor's Report. 5. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / period. 6. During this pandemic business operations and financial position has revealed that there has been no significant impact on company's financial results as at 31st December, 2020. However the impact assessment of COVID-19 will be a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these financial results. The Company will continue to monitor such impact to future economic conditions.

Place: Hyderabad  
Date: 05/02/2021

For Pharmaids Pharmaceuticals Limited

*Padma*  
S. Padmaja Kalyani



Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040 - 40122151  
CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW  
Email : pharmaids125@gmail.com , Web : www.pharmaids.com





# Pharmaids Pharmaceuticals Limited

**Pharmaids Pharmaceuticals Limited**  
**Balance Sheet as at 31st December, 2020**

Rs. (In Lakhs)

	Particulars	Note No.	Figures as at the end of 31.12.2020	Figures as at the end of 31.03.2020
	1	2	3	4
<b>1</b>	<b>ASSETS</b>			
	<b>Non-current assets</b>			
	(a) Property, Plant and Equipment		5.10	8.31
	(b) Capital work-in-progress		45.00	45.00
	(c) Investment Property		-	-
	(d) Goodwill		-	-
	(e) Other Intangible assets		-	-
	(f) Intangible assets under development		-	-
	(g) Biological Assets other than bearer plants		-	-
	(h) Financial Assets			
	(i) Investments		-	-
	(ii) Trade receivables		75.85	75.85
	(iii) Loans		632.43	643.35
	(iv) Others (to be specified)		-	-
	(i) Deferred tax assets (net)		34.58	34.58
	(j) Other non-current assets		-	-
<b>2</b>	<b>Current assets</b>			
	(a) Inventories		127.64	-
	(b) Financial Assets			
	(i) Investments		-	-
	(ii) Trade receivables		93.71	-
	(iii) Cash and cash equivalents		7.47	2.18
	(iv) Bank balances other than (iii) above		-	-
	(v) Loans		36.55	36.55
	(vi) Others (to be specified)		-	-
	(c) Current Tax Assets (Net)		-	-
	(d) Other current assets		16.71	-
	<b>Total Assets</b>		<b>1,075.04</b>	<b>845.82</b>
	<b>EQUITY AND LIABILITIES Equity</b>			
	(a) Equity Share capital		1,026.88	1,026.88
	(b) Other Equity		(178.54)	(183.57)
	<b>LIABILITIES</b>			
<b>1</b>	<b>Non-current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings		-	-
	(ii) Trade payables		-	-
	(iii) Other financial liabilities (other than those specified in item (i) and (ii))		-	-
	(b) Provisions		-	-
	(c) Deferred tax liabilities (Net)		-	-
	(d) Other non-current liabilities		-	-
<b>2</b>	<b>Current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings		-	-
	(ii) Trade payables		223.42	1.07
	(iii) Other financial liabilities (other than those specified in item (i) and (ii))		-	-
	(b) Other current liabilities		1.19	1.44
	(c) Provisions		2.08	-
	(d) Current Tax Liabilities (Net)		-	-
	<b>Total Equity and Liabilities</b>		<b>1,075.04</b>	<b>845.82</b>

For Pharmaids Pharmaceuticals Limited

*Padma*  
S.Padmaja Kalyani



Place: Hyderabad  
Date: 05/02/2021

Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500043 Ph: 040-40122151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP465

Email : [pharmaids125@gmail.com](mailto:pharmaids125@gmail.com) , Web : [www.pharmaids.com](http://www.pharmaids.com)



# Pharmaids Pharmaceuticals Limited

## Pharmaids Pharmaceuticals Limited

### Statement of Cash Flows for the Nine month ended 31st December 2020

Rs. (In Lakhs)

	Particulars	Figures as at the end of 31.12.2020 (Unaudited)	Figures as at the end of 31.12.2019 (Audited)
<b>A</b>	<b>CASHFLOW FROM OPERATING ACTIVITIES:</b>		
	Net Profit before Tax	7.11	(33.92)
	Adjustment for:		
	Depreciation and Amortization	3.36	2.79
	Interest Charged	-	0.00
	Interest Income	-	-
	Dividend Income/Gain on sale of Investments	-	-
	Provision / write off for doubtful trade receivables	-	-
	Deferred Tax	-	-
	<b>Operating Profit before change in working capital</b>	<b>10.47</b>	<b>(31.13)</b>
	<b>Working capital changes:</b>		
	Changes in Inventories	(127.64)	-
	Changes in Trade Receivables	(93.71)	13.12
	Change in Short term loans and advances	(0.10)	33.54
	Changes in Trade payables	222.36	(15.96)
	Changes in Other liabilities	(0.25)	(3.92)
	Changes in Provisions	-	-
	Changes in Other Current Assets	(16.71)	-
	<b>Cash generated from Operations</b>	<b>(5.58)</b>	<b>(4.35)</b>
	Direct tax paid (Net of Refunds)	-	(0.27)
	<b>Net Cash inflow from Operating Activities (A)</b>	<b>(5.58)</b>	<b>(4.08)</b>
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES:</b>		
	Proceeds from Sale Asset	-	-
	Government assistance	-	-
	Interest received	-	-
	Dividend Income /Gain on Sale of Investments received	-	-
	Purchase of property, plant & equipments, intangible assets and Capital Advance	(0.15)	(3.70)
	Investment in Associate	-	-
	Intangible assets under development	-	-
	Long term loans and Advances Given/(Repaid)	11.01	(1.30)
	<b>Net Cash inflow from Investing Activities (B)</b>	<b>10.86</b>	<b>(5.00)</b>
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES:</b>		
	Proceeds from borrowings	0.00	-
	Net increase/ (decrease) in working capital demand loans	-	-
	Payment of lease liabilities	-	-
	Increase in Restricted Bank Balances other than Cash & Cash Equivalents	-	-
	Dividends paid (including distribution tax)	-	-
	Interest and other finance costs (including borrowing cost capitalised)	-	(0.00)
	<b>Net Cash inflow from Financing Activities (C)</b>	<b>0.00</b>	<b>(0.00)</b>
<b>I</b>	<b>Net (decrease)/increase in cash and cash equivalents (A+B+C)</b>	<b>5.28</b>	<b>(9.08)</b>
<b>II</b>	<b>a) Cash and Cash Equivalents at the beginning of the year</b>	<b>2.19</b>	<b>10.88</b>
	<b>b) Effect of Exchange difference on restatement of foreign currency cash and cash equivalents</b>		
	<b>c) Effect of Fairvalue change of investment held for Trading</b>		
<b>III</b>	<b>Cash and Cash Equivalents at the end of the year (I+II)</b>	<b>7.47</b>	<b>1.80</b>
<b>IV</b>	<b>Cash and Cash Equivalents at the end of the year</b>		
	Balances with Banks	2.69	1.58
	Cash on Hand	4.77	0.22
	<b>Total Cash and Cash Equivalents</b>	<b>7.47</b>	<b>1.80</b>

Place: Hyderabad  
Date: 05/02/2021

For Pharmaids Pharmaceuticals Limited

*Padma*  
S.Padmaja Kalyani



Office Address : 503, Amrutha Estate, Himayath Nagar, Hyderabad - 500029. Ph: 040-2351151

CIN No: L52520TG1989LC009679, GSTIN No : 36AABCP4657N2ZW

Email : [pharmaids125@gmail.com](mailto:pharmaids125@gmail.com) , Web : [www.pharmaids.com](http://www.pharmaids.com)



**INDEPENDENT AUDITOR'S REVIEW REPORT ON  
REVIEW OF INTERIM FINANCIAL RESULTS**

To  
The Board of Directors,  
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited Financial Results of **PHARMAIDS PHARMACEUTICALS LIMITED** ("the Company") for the Quarter/ Nine Months Ended 31<sup>st</sup> December, 2020 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Scheme of Amalgamation of Emergent Bio Naturals Limited (EBNL) with Pharmaids Pharmaceuticals Limited was approved by the National Company Law Tribunal vide its order dated 27th September, 2019. The certified copy of the NCLT order was filed with Registered of Companies on 12th October, 2019 consequently the Scheme became operative, and effective date is 1st April, 2018 (Appointed Date). The Company has accounted the Amalgamation as per Appendix C of IND AS 103 Business Combination, the financial information in respect of prior periods has been restated as if the business combination had occurred on April 1st, 2018.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Previously issued financial information of the Company for the quarter ended and Nine months ended 31<sup>st</sup> December, 2019 included in the Statement, have been restated to give effect to the Scheme of Amalgamation ("the Scheme") of Pharmaids Pharmaceuticals Limited (PPL) with Emergent Bio Naturals Limited, as explained in note 5 to the Statement.

The adjustments made to the previously issued financial information to give effect to the Scheme have been reviewed by us. Our report is not modified in respect of this matter.

Place : Hyderabad

Date : 05<sup>th</sup> February, 2021

UDIN: 21231499AAAAAW4152

**For PPKG & CO**

Chartered Accountants

FRN No. 009655S



**SWETHA TOSHWIHAL**

(Partner)

M. No. 231499